Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma

Leuk Lymphoma. 2006 Nov;47(11):2289-300. doi: 10.1080/10428190600822128.


Multiple myeloma is a genetically heterogenous disease with a wide variety of characterized genetic aberrations. Until recently, the impact of these aberrations on patient outcome was not known. However, in the last 5-10 years, several genetic markers have been linked to patient outcome. One of the strongest predictors of outcome identified to date is t(4;14)(p16;q32). Although this translocation is tightly linked to chromosome 13 deletions, another poor prognosis marker, it is becoming apparent that the translocation and not the deletion of 13 is the important factor. Unfortunately, despite the known association with outcome, an understanding of the mechanism(s) whereby the translocation contributes to developing and maintaining this aggressive form of myeloma remains elusive.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Carrier Proteins / genetics
  • Carrier Proteins / metabolism
  • Chromosomes, Human, Pair 4 / genetics*
  • Heterozygote
  • Histone-Lysine N-Methyltransferase
  • Humans
  • Multiple Myeloma / genetics*
  • Multiple Myeloma / metabolism
  • Multiple Myeloma / pathology
  • Receptor, Fibroblast Growth Factor, Type 3 / metabolism
  • Repressor Proteins / genetics
  • Repressor Proteins / metabolism
  • Time Factors


  • Carrier Proteins
  • Repressor Proteins
  • Histone-Lysine N-Methyltransferase
  • NSD2 protein, human
  • Receptor, Fibroblast Growth Factor, Type 3